Condition: Prostate Cancer · Prostatic Neoplasms · Sponsor: Dana-Farber Cancer Institute
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
This description comes directly from the study's public registry record.
Alicia Morgans, MD · 857-215-1605 · aliciak_morgans@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute at Foxborough | Foxborough, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05765500